SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Geschlossen

1.418 4.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.357

Max

1.422

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.009
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-51M 946M
Vorheriger Eröffnungskurs	-2.77
Vorheriger Schlusskurs	1.418

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Dez. 2025, 20:41 UTC

Ergebnisse

Wichtige Markttreiber

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. Dez. 2025, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. Dez. 2025, 17:43 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. Dez. 2025, 17:01 UTC

Ergebnisse

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. Dez. 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. Dez. 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. Dez. 2025, 21:37 UTC

Ergebnisse

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. Dez. 2025, 21:36 UTC

Ergebnisse

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. Dez. 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. Dez. 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. Dez. 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. Dez. 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. Dez. 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Dez. 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. Dez. 2025, 16:33 UTC

Market Talk

Ergebnisse

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.